Clinical-stage biopharmaceutical company Syndax Pharmaceuticals, Inc. has received Orphan Drug Designation for axatilimab from the U.S. Food and Drug Administration (FDA) for treating patients with idiopathic pulmonary fibrosis (IPF).  Axatilimab is a monoclonal antibody that targets CSF-1R, a cell surface protein. Syndax Pharmaceuticals (SNDX) Chief Executive Officer Briggs W. Morrison, M.D., said, “IPF is a serious, life-limiting orphan disease, and today’s Orphan Drug Designation validates axatilimab’s potential to serve as an effective therapeutic option for the currently-underserved patients living with this rare disease.
https://www.tipranks.com/news/syndax-pharmas-axatilimab-receives-orphan-drug-designation-for-treatment-of-chronic-lung-disease
Syndax Pharmaceuticals (NASDAQ:SNDX)
Historical Stock Chart
From Jun 2021 to Jul 2021 Click Here for more Syndax Pharmaceuticals Charts.
Syndax Pharmaceuticals (NASDAQ:SNDX)
Historical Stock Chart
From Jul 2020 to Jul 2021 Click Here for more Syndax Pharmaceuticals Charts.